Effect of Atorvastatin on Inflammatory Markers in Hemodialysis Patients
Noha Abdel Hamid Omran;
Abstract
Our study is a prospective clinical trial in which 53 adult prevalent hemodialysis patients were recruited from hemodialysis units of Ain Shams University Hospitals to investigate the possible anti-inflammatory effects of atorvastatin in ESRD patients undergoing hemodialysis.
Patients were divided into 2 groups:
Group 1 (Drug group): 33 patients who received 20 mg of atorvastatin daily for 6 months. They were further subdivided into 2 groups according to their baseline total cholesterol level;
Group A (Dyslipidemic group): included 12 patients with baseline total cholesterol of ≥ 200 mg/dL and Group B (Normolipidemic group): included 21 patients with baseline total cholesterol of < 200 mg/dL.
Patients were divided into 2 groups:
Group 1 (Drug group): 33 patients who received 20 mg of atorvastatin daily for 6 months. They were further subdivided into 2 groups according to their baseline total cholesterol level;
Group A (Dyslipidemic group): included 12 patients with baseline total cholesterol of ≥ 200 mg/dL and Group B (Normolipidemic group): included 21 patients with baseline total cholesterol of < 200 mg/dL.
Other data
| Title | Effect of Atorvastatin on Inflammatory Markers in Hemodialysis Patients | Other Titles | تأثير عقار الأتورفاستاتين على دلالات الإلتهاب في مرضى الغسيل الكلوى | Authors | Noha Abdel Hamid Omran | Issue Date | 2018 |
Recommend this item
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.